Johns Hopkins Medicine published clinical validation data supporting the first FDA-cleared rapid urine test for invasive aspergillosis. The result adds a point-of-care compatible specimen pathway aimed at earlier detection in high-risk patients, addressing a diagnostic gap where delays can drive poor outcomes.